Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 62

1.

Toxicokinetics and analytical toxicology of flualprazolam: metabolic fate, isozyme mapping, human plasma concentration, and main urinary excretion products.

Wagmann L, Manier SK, Bambauer TP, Felske C, Eckstein N, Flockerzi V, Meyer MR.

J Anal Toxicol. 2020 Feb 27. pii: bkaa019. doi: 10.1093/jat/bkaa019. [Epub ahead of print]

PMID:
32104896
2.

The metabolic fate of two new psychoactive substances - 2-aminoindane and N-methyl-2-aminoindane - studied in vitro and in vivo to support drug testing.

Manier SK, Felske C, Eckstein N, Meyer MR.

Drug Test Anal. 2020 Jan;12(1):145-151. doi: 10.1002/dta.2699. Epub 2019 Nov 25.

PMID:
31667988
3.

Thioredoxin Confers Intrinsic Resistance to Cytostatic Drugs in Human Glioma Cells.

Haas B, Schütte L, Wos-Maganga M, Weickhardt S, Timmer M, Eckstein N.

Int J Mol Sci. 2018 Sep 21;19(10). pii: E2874. doi: 10.3390/ijms19102874.

4.

Inhibition of the PI3K but not the MEK/ERK pathway sensitizes human glioma cells to alkylating drugs.

Haas B, Klinger V, Keksel C, Bonigut V, Kiefer D, Caspers J, Walther J, Wos-Maganga M, Weickhardt S, Röhn G, Timmer M, Frötschl R, Eckstein N.

Cancer Cell Int. 2018 May 4;18:69. doi: 10.1186/s12935-018-0565-4. eCollection 2018.

5.

Reduced longitudinal cardiac strain in asthma patients.

Tuleta I, Eckstein N, Aurich F, Nickenig G, Schaefer C, Skowasch D, Schueler R.

J Asthma. 2019 Apr;56(4):350-359. doi: 10.1080/02770903.2018.1466311. Epub 2018 May 18.

PMID:
29668337
6.

Asthma is associated with atherosclerotic artery changes.

Tuleta I, Skowasch D, Aurich F, Eckstein N, Schueler R, Pizarro C, Schahab N, Nickenig G, Schaefer C, Pingel S.

PLoS One. 2017 Oct 26;12(10):e0186820. doi: 10.1371/journal.pone.0186820. eCollection 2017.

7.

Is sunitinib a Narrow Therapeutic Index Drug? - A systematic review and in vitro toxicology-analysis of Sunitinib vs. Imatinib in cells from different tissues.

Haas B, Weber-Lassalle K, Frötschl R, Eckstein N.

Regul Toxicol Pharmacol. 2016 Jun;77:25-34. doi: 10.1016/j.yrtph.2016.02.010. Epub 2016 Feb 23. Review.

PMID:
26924275
8.

Association between Metabolic Syndrome and Bone Mineral Density--Data from the Berlin Aging Study II (BASE-II).

Eckstein N, Buchmann N, Demuth I, Steinhagen-Thiessen E, Nikolov J, Spira D, Eckardt R, Norman K.

Gerontology. 2016;62(3):337-44. doi: 10.1159/000434678. Epub 2016 Jan 29.

PMID:
26821158
9.

Efficacy, safety and regulatory status of SGLT2 inhibitors: focus on canagliflozin.

Haas B, Eckstein N, Pfeifer V, Mayer P, Hass MD.

Nutr Diabetes. 2014 Nov 3;4:e143. doi: 10.1038/nutd.2014.40.

10.

Systemic therapy of Cushing's syndrome.

Eckstein N, Haas B, Hass MD, Pfeifer V.

Orphanet J Rare Dis. 2014 Aug 5;9:122. doi: 10.1186/s13023-014-0122-8. Review.

11.

Clinical pharmacology and regulatory consequences of GnRH analogues in prostate cancer.

Eckstein N, Haas B.

Eur J Clin Pharmacol. 2014 Jul;70(7):791-8. doi: 10.1007/s00228-014-1682-1. Epub 2014 Apr 23. Review.

12.

Clinical pharmacology of tyrosine kinase inhibitors becoming generic drugs: the regulatory perspective.

Eckstein N, Röper L, Haas B, Potthast H, Hermes U, Unkrig C, Naumann-Winter F, Enzmann H.

J Exp Clin Cancer Res. 2014 Feb 7;33:15. doi: 10.1186/1756-9966-33-15.

13.

Targeting adipose tissue.

Haas B, Schlinkert P, Mayer P, Eckstein N.

Diabetol Metab Syndr. 2012 Oct 27;4(1):43. doi: 10.1186/1758-5996-4-43.

14.

[Platinum-based chemotherapy in triple negative breast cancer].

Eckstein N, Haas B.

Dtsch Med Wochenschr. 2012 Feb;137(7):333-6. doi: 10.1055/s-0031-1298891. Epub 2012 Feb 8. Review. German.

PMID:
22318849
15.

Platinum resistance in breast and ovarian cancer cell lines.

Eckstein N.

J Exp Clin Cancer Res. 2011 Oct 4;30:91. doi: 10.1186/1756-9966-30-91. Review.

16.

Overcoming cisplatin resistance of ovarian cancer cells by targeted liposomes in vitro.

Krieger ML, Eckstein N, Schneider V, Koch M, Royer HD, Jaehde U, Bendas G.

Int J Pharm. 2010 Apr 15;389(1-2):10-7. doi: 10.1016/j.ijpharm.2009.12.061. Epub 2010 Jan 7.

PMID:
20060458
17.

Y-box-binding protein YB-1 identifies high-risk patients with primary breast cancer benefiting from rapidly cycled tandem high-dose adjuvant chemotherapy.

Gluz O, Mengele K, Schmitt M, Kates R, Diallo-Danebrock R, Neff F, Royer HD, Eckstein N, Mohrmann S, Ting E, Kiechle M, Poremba C, Nitz U, Harbeck N.

J Clin Oncol. 2009 Dec 20;27(36):6144-51. doi: 10.1200/JCO.2008.19.6261. Epub 2009 Nov 9.

PMID:
19901122
18.

NF546 [4,4'-(carbonylbis(imino-3,1-phenylene-carbonylimino-3,1-(4-methyl-phenylene)-carbonylimino))-bis(1,3-xylene-alpha,alpha'-diphosphonic acid) tetrasodium salt] is a non-nucleotide P2Y11 agonist and stimulates release of interleukin-8 from human monocyte-derived dendritic cells.

Meis S, Hamacher A, Hongwiset D, Marzian C, Wiese M, Eckstein N, Royer HD, Communi D, Boeynaems JM, Hausmann R, Schmalzing G, Kassack MU.

J Pharmacol Exp Ther. 2010 Jan;332(1):238-47. doi: 10.1124/jpet.109.157750. Epub 2009 Oct 8.

PMID:
19815812
19.

Hyperactivation of the insulin-like growth factor receptor I signaling pathway is an essential event for cisplatin resistance of ovarian cancer cells.

Eckstein N, Servan K, Hildebrandt B, Pölitz A, von Jonquières G, Wolf-Kümmeth S, Napierski I, Hamacher A, Kassack MU, Budczies J, Beier M, Dietel M, Royer-Pokora B, Denkert C, Royer HD.

Cancer Res. 2009 Apr 1;69(7):2996-3003. doi: 10.1158/0008-5472.CAN-08-3153. Epub 2009 Mar 24.

20.

Acquired cisplatin resistance in the head-neck cancer cell line Cal27 is associated with decreased DKK1 expression and can partially be reversed by overexpression of DKK1.

Gosepath EM, Eckstein N, Hamacher A, Servan K, von Jonquieres G, Lage H, Györffy B, Royer HD, Kassack MU.

Int J Cancer. 2008 Nov 1;123(9):2013-9. doi: 10.1002/ijc.23721.

21.

The Y-box binding protein YB-1 is associated with progressive disease and mediates survival and drug resistance in multiple myeloma.

Chatterjee M, Rancso C, Stühmer T, Eckstein N, Andrulis M, Gerecke C, Lorentz H, Royer HD, Bargou RC.

Blood. 2008 Apr 1;111(7):3714-22. Epub 2007 Nov 15.

PMID:
18006704
22.

Epidermal growth factor receptor pathway analysis identifies amphiregulin as a key factor for cisplatin resistance of human breast cancer cells.

Eckstein N, Servan K, Girard L, Cai D, von Jonquieres G, Jaehde U, Kassack MU, Gazdar AF, Minna JD, Royer HD.

J Biol Chem. 2008 Jan 11;283(2):739-50. Epub 2007 Oct 17.

23.

In vitro differentiation of human dental follicle cells with dexamethasone and insulin.

Morsczeck C, Moehl C, Götz W, Heredia A, Schäffer TE, Eckstein N, Sippel C, Hoffmann KH.

Cell Biol Int. 2005 Jul;29(7):567-75.

PMID:
15951208
24.

Novel modulators to overcome P-glycoprotein-mediated multidrug resistance in tumor cells.

Müller H, Klinkhammer W, Kassack MU, Eckstein N, Wiese M.

Int J Clin Pharmacol Ther. 2004 Nov;42(11):644-5. No abstract available.

PMID:
15598032
25.
26.

Pharmacological characterization of the benz[d]indolo[2,3-g]azecine LE300, a novel type of a nanomolar dopamine receptor antagonist.

Kassack MU, Höfgen B, Decker M, Eckstein N, Lehmann J.

Naunyn Schmiedebergs Arch Pharmacol. 2002 Dec;366(6):543-50. Epub 2002 Oct 11.

PMID:
12444495
27.

Functional screening of G protein-coupled receptors by measuring intracellular calcium with a fluorescence microplate reader.

Kassack MU, Höfgen B, Lehmann J, Eckstein N, Quillan JM, Sadée W.

J Biomol Screen. 2002 Jun;7(3):233-46.

PMID:
12097186
28.

Allosteric modulation of muscarinic receptor signaling: alcuronium-induced conversion of pilocarpine from an agonist into an antagonist.

Zahn K, Eckstein N, Tränkle C, Sadée W, Mohr K.

J Pharmacol Exp Ther. 2002 May;301(2):720-8.

PMID:
11961078
29.

Hormonal regulation of peripheral benzodiazepine receptor binding properties is mediated by subunit interaction.

Golani I, Weizman A, Leschiner S, Spanier I, Eckstein N, Limor R, Yanai J, Maaser K, Scherübl H, Weisinger G, Gavish M.

Biochemistry. 2001 Aug 28;40(34):10213-22.

PMID:
11513599
30.

The effects of 17beta-estradiol on ectopic rhythm in human atrial strips.

Pines A, Weiss A, Eckstein N, Nadler E, Barnea O, Ayalon D, Shavit G.

Maturitas. 1999 Oct 24;33(2):171-3. No abstract available.

PMID:
10597882
31.

Hormone replacement and simvastatin in the therapy of hypercholesterolemic postmenopausal women.

Averbuch M, Ayalon D, Eckstein N, Dotan I, Shapira I, Levo Y, Pines A.

J Med. 1998;29(5-6):343-50.

PMID:
10503169
32.

Hormone replacement therapy enhances postprandial lipid metabolism in postmenopausal women.

Weintraub M, Grosskopf I, Charach G, Eckstein N, Rubinstein A.

Metabolism. 1999 Sep;48(9):1193-6.

PMID:
10484063
33.

Effect of estradiol on rat ileum.

Pines A, Eckstein N, Dotan I, Ayalon D, Varon D, Barnea O, Shavit G.

Gen Pharmacol. 1998 Nov;31(5):735-6.

PMID:
9809470
34.

Fluctuations of lipid and lipoprotein levels in hyperlipidemic postmenopausal women receiving hormone replacement therapy.

Weintraub MS, Grosskopf I, Charach G, Eckstein N, Ringel Y, Maharshak N, Rotmensch HH, Rubinstein A.

Arch Intern Med. 1998 Sep 14;158(16):1803-6.

PMID:
9738610
35.

The effects of sublingual estradiol on left ventricular function at rest and exercise in postmenopausal women: an echocardiographic assessment.

Pines A, Fisman EZ, Drory Y, Shapira I, Averbuch M, Eckstein N, Motro M, Levo Y, Ayalon D.

Menopause. 1998 Summer;5(2):79-85.

PMID:
9689200
36.

Exercise echocardiography in postmenopausal hormone users with mild systemic hypertension.

Pines A, Fisman EZ, Shapira I, Drory Y, Weiss A, Eckstein N, Levo Y, Averbuch M, Motro M, Rotmensch HH, Ayalon D.

Am J Cardiol. 1996 Dec 15;78(12):1385-9.

PMID:
8970411
37.

Genetic relationship between dopamine transporter gene and schizophrenia: linkage and association.

Maier W, Minges J, Eckstein N, Brodski C, Albus M, Lerer B, Hallmayer J, Fimmers R, Ackenheil M, Ebstein RE, Borrmann M, Lichtermann D, Wildenauer DB.

Schizophr Res. 1996 May;20(1-2):175-80.

PMID:
8794507
38.

A case of hypergonadotrophinaemia associated with very high isolated concentrations of immunologically and biologically active luteinizing hormone.

Eckstein N, Huhtaniemi I, Vagman I, Pakarinen P, Limor R, Ayalon D.

Hum Reprod. 1996 Jan;11(1):64-7.

PMID:
8671158
39.

Acute effects of 17 beta-estradiol on the rat heart.

Eckstein N, Nadler E, Barnea O, Shavit G, Ayalon D.

Am J Obstet Gynecol. 1994 Sep;171(3):844-8.

PMID:
8092238
40.

The effect of the hypoestrogenic state, induced by gonadotropin-releasing hormone agonist, on Doppler-derived parameters of aortic flow.

Eckstein N, Pines A, Fisman EZ, Fisch B, Limor R, Vagman I, Barnan R, Ayalon D.

J Clin Endocrinol Metab. 1993 Oct;77(4):910-2.

PMID:
8408464
41.

Inhibitory effect of a highly potent antagonist of LH releasing hormone (SB-75) on the pituitary gonadal axis in the intact and castrated rat.

Ayalon D, Farhi Y, Comaru-Schally AM, Schally AV, Eckstein N, Vagman I, Limor R.

Neuroendocrinology. 1993 Aug;58(2):153-9.

PMID:
8264861
42.
43.

Another look at co-treatment with growth hormone and human menopausal gonadotrophins in poor ovarian responders.

Levy T, Limor R, Villa Y, Eshel A, Eckstein N, Vagman I, Lidor A, Ayalon D.

Hum Reprod. 1993 Jun;8(6):834-9.

PMID:
8345071
44.

[Transvaginal fallopian tubal catheterization: clinical applications and limitations].

Eckstein N, Papo J, Vagman I, Lidor A, Oron DF, Chen Z, Ayalon D.

Harefuah. 1992 Dec 1;123(11):471-5. Review. Hebrew. No abstract available.

PMID:
1487206
45.

Digital road mapping image--a novel fluoroscopic real-time guide for selective transcervical catheterization in the treatment of proximal tubal obstruction.

Eckstein N, Orron DE, Vagman I, Papo J, Lidor A, Chen Z, Ayalon D.

Fertil Steril. 1992 Oct;58(4):850-3.

PMID:
1426340
46.

Calcium homeostasis, bone metabolism and safety aspects during long-term treatment with a GnRH agonist.

Eckstein N, Foldes J, Feinstein Y, Vagman I, Eshel A, Steinberg R, Statter M, Limor R, Ayalon D.

Maturitas. 1992 Aug;15(1):25-32.

PMID:
1388219
47.

Pregnancy outcome following early exposure to maternal luteinizing-hormone-releasing hormone agonist (buserelin).

Dicker D, Goldman JA, Vagman I, Eckstein N, Ayalon D.

Hum Reprod. 1989 Apr;4(3):250-1.

PMID:
2497132
48.

Induction of ovulation with D-Trp6-LHRH combined with purified FSH in patients with polycystic ovarian disease.

Ayalon D, Ben-David M, Wohl R, Jaffe R, Vagman I, Eckstein N, Limor R, Comaru-Schally AM, Schally AV.

Gynecol Endocrinol. 1988 Dec;2(4):319-30.

PMID:
2976573
49.

Diagnosis of a small ovarian tumor (androgen secreting) by magnetic resonance: a new noninvasive procedure.

Ayalon D, Graif M, Hetman-Peri M, Abramowicz J, Eckstein N, Vagman I, Papo J, Itzhak Y, Caspi E.

Am J Obstet Gynecol. 1988 Oct;159(4):903-5.

PMID:
3177545
50.

Sonographic monitoring of ovarian volume during LHRH analogue therapy in women with polycystic ovarian syndrome.

Jaffe R, Abramowicz J, Eckstein N, Vagman I, Fejgin M, Ayalon D.

J Ultrasound Med. 1988 Apr;7(4):203-6.

PMID:
2966864

Supplemental Content

Loading ...
Support Center